

# **Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033**

<https://marketpublishers.com/r/N8EFC1210311EN.html>

Date: June 2023

Pages: 385

Price: US\$ 5,500.00 (Single User License)

ID: N8EFC1210311EN

## **Abstracts**

### Global NGS Market: Industry Overview

The global NGS market was valued at \$6.76 billion in 2022 and is expected to reach \$28.47 billion by 2033, growing at a CAGR of 13.97% during the forecast period 2023-2033. The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, the growing prevalence of non-communicable disorders, and the advancement in the performance of NGS platforms.

### Market Lifecycle Stage

The global NGS market is highly consolidated. This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing. The opportunity for growth of the global NGS market lies in the development of economical and portable technologies.

### Impact of COVID-19

NGS has played a crucial role in the genomic surveillance of SARS-CoV-2, the virus responsible for COVID-19. Sequencing the viral genome has helped in tracking the spread of different variants and understanding their genetic characteristics, which has been essential for public health efforts, vaccine development, and treatment strategies. NGS has been employed in studies investigating the genetic susceptibility to COVID-19

and its severity. By sequencing the genomes of affected individuals, researchers have sought to identify genetic variations associated with the risk of infection, disease progression, and response to treatment.

However, while NGS testing shot up in the research laboratories studying the transmission of the SARS-CoV-2 virus, NGS testing in the clinical setting witnessed a significant drop. The global supply chain for NGS instruments, consumables, and reagents experienced severe disruptions due to the pandemic. Manufacturing and shipping delays impacted the availability of NGS products and tests, especially in developing regions such as the Middle East, Africa, or Rest-of-the-World.

Market Segmentation:

Segmentation 1: by Offering

Consumables

Library Preparation Kits

Sequencing Kits

Equipment

Services

The global NGS market (by offering) is expected to be dominated by the consumables segment.

Segmentation 2: by Company

Illumina, Inc.

Thermo Fisher Scientific Inc.

Pacific BioSciences of California, Inc.

Oxford Nanopore Technologies plc.

## Other Companies

The global NGS market (by company) is expected to be dominated by Illumina, Inc.

### Segmentation 3: by Throughput

High- and Ultra-High-Throughput

Medium-Throughput

Low-Throughput

The global NGS market (by throughput) is expected to be dominated by the high- and ultra-high throughput segment.

### Segmentation 4: by Technology Type

Sequencing by Synthesis

In Torrent Semiconductor Sequencing

Single Molecule Real-Time Sequencing

Nanopore Sequencing Technology

Other Technologies

The global NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.

### Segmentation 5: by Sequencing

Whole Genome Sequencing

Whole Exome Sequencing

## Targeted Sequencing

The global NGS market (by sequencing) is expected to be dominated by the targeted sequencing segment.

### Segmentation 6: by Application

#### Clinical Diagnostics

Oncology

Non-Oncology

#### Research

Oncology

Non-Oncology

The global NGS market (by application) is expected to be dominated by the research segment. Within further sub-segmentation, the market is expected to be dominated by the oncology segment.

### Segmentation 7: by End User

Academic and Research Institutes

Clinical Laboratories

Pharmaceutical and Biotechnology Companies

Other End Users

The global NGS market (by end user) is expected to be dominated by the academic and research institutes segment.

## Segmentation 8: by Country

North America - U.S., Canada

Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe

Asia-Pacific - Japan, India, China, South Korea, Australia, Singapore, New Zealand, and Rest-of-Asia-Pacific

Middle East - U.A.E., K.S.A., Israel, Rest-of-Middle East

Rest-of-the-World - Latin America, Rest-of-Rest-of-the-World

\*Note: Each country is further segmented by offering, equipment (units), and company.

## Recent Developments in the Global NGS Market

In April 2023, NGeneBio signed a business agreement with Agilent Technologies, Inc.'s Korea-based subsidiary, to expand the NGS precision diagnosis in South Korea and abroad.

In March 2023, Sophia Genetics partnered with Agilent Technologies Inc. to integrate its Sophia DDM Platform with Agilent Technologies Inc.'s research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) assay kit.

In March 2023, Thermo Fisher Scientific Inc. collaborated with Pfizer to expand access to NGS-based lung and breast cancer testing in more than 30 countries.

In January 2023, Qiagen N.V. completed the acquisition of Verogen, Inc. in order to deploy next-generation biometrics for forensic and molecular testing.

In October 2022, Pacific Biosciences of California, Inc. introduced two new sequencing systems, namely, Revio and Onso.

In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.

## Demand - Drivers and Limitations

The following are the drivers for the global NGS market:

Decreasing Cost of Genome Sequencing

Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings

Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare

Advantages of NGS Technology Over Other Technologies

The market is expected to face some limitations as well due to the following challenges:

Concerns Surrounding Privacy of Patient Genomic Data

Lack of Complete Reimbursement Coverage for NGS Testing

How can this report add value to an organization?

**Type:** The global NGS market has been extensively segmented on the basis of various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

**Growth/Marketing Strategy:** Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., nearly 85% of the total developments in the global NGS market.

**Competitive Strategy:** The global NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the global NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.

## Key Companies Profiled

BGI Group

Illumina, Inc.

Thermo Fisher Scientific Inc.

Pacific Biosciences of California, Inc.

Oxford Nanopore Technologies plc.

Agilent Technologies, Inc.

Qiagen N.V.

Pillar Biosciences

Burning Rock Biotech Limited

Singular Genomics Systems, Inc.

DANAHER CORPORATION

F. Hoffmann-La Roche Ltd

Twist Bioscience Corporation

Revvity, Inc.

Centogene N.V.

Element Biosciences

Ultima Genomics

Genes2me

LifeStrands Genomics Pte. Ltd.

Alitheia Genomics

Real Seq Biosciences



## Contents

### 1 MARKETS

#### 1.1 Product Definition

##### 1.1.1 Inclusion and Exclusion Criteria

#### 1.2 Market Scope

##### 1.2.1 Scope of the Study

##### 1.2.2 Key Questions Answered in the Report

#### 1.3 Research Methodology

##### 1.3.1 Global Next-Generation IVD Market: Research Methodology

##### 1.3.2 Data Sources

###### 1.3.2.1 Primary Data Sources

###### 1.3.2.2 Secondary Data Sources

##### 1.3.3 Market Estimation Model

##### 1.3.4 Criteria for Company Profiling

### 2 MARKET OVERVIEW

#### 2.1 Introduction

##### 2.1.1 Global Next-Generation IVD Market Outlook

###### 2.1.1.1 POC-IVD

###### 2.1.1.2 Global Diagnostic Expenditures

###### 2.1.1.3 Pricing Patterns of Next-Generation IVD

##### 2.1.2 Market Size and Growth Potential

###### 2.1.2.1 Short-Term Impact (2020-2025)

###### 2.1.2.2 Long-Term Impact (2026-2033)

##### 2.1.3 Product Benchmarking by Next- Generation In-vitro Diagnostics Market, (by Type)

#### 2.2 COVID-19 Impact on the Next-Generation IVD Market

##### 2.2.1 Impact on Operations

##### 2.2.2 COVID-19 Impact: Current Scenario of the Market

##### 2.2.3 Pre-COVID Assessment

##### 2.2.4 Post-COVID-19 Market Assessment

### 3 INDUSTRY ANALYSIS

#### 3.1 Legal Requirements

##### 3.1.1 Legal Requirements and Framework in the U.S.

- 3.1.2 Legal Requirements and Framework in Europe
- 3.1.3 Legal Requirements and Framework in Asia-Pacific
- 3.1.4 Legal Requirement and Framework in Latin America

## **4 MARKET DYNAMICS**

- 4.1 Overview
- 4.2 Impact Analysis
- 4.3 Market Drivers
  - 4.3.1 Technological Advancements in Next-Generation In-Vitro Diagnostics Transforming Healthcare System
  - 4.3.2 Rising Demand of POC Testing Boosting Next-Generation IVD Market
  - 4.3.3 Growing Incidence of Chronic and Acute Diseases Demanding for Early Treatment
  - 4.3.4 Boost in the Next-Generation IVD Market during COVID-19 Pandemic
- 4.4 Market Challenges
  - 4.4.1 Regulatory Hurdles Related to Next-Generation IVD Technologies
  - 4.4.2 Poor Reimbursement Scenario
- 4.5 Market Opportunities
  - 4.5.1 Rising Number of Next-Generation IVD Companies Involved in Business Expansion
  - 4.5.2 Inclination of Emerging Companies toward Next-Generation IVD

## **5 COMPETITIVE LANDSCAPE**

- 5.1 Overview
- 5.2 Corporate Strategies
  - 5.2.1 Acquisitions
  - 5.2.2 Synergistic Activities
- 5.3 Business Strategies
  - 5.3.1 Product Launches and Approvals
  - 5.3.2 Business Expansions, Fundings, and Other Activities
- 5.4 Market Share Analysis
  - 5.4.1 Market Share Analysis (by Company)
- 5.5 Growth Share Analysis
  - 5.5.1 Growth Share Analysis (by Product)

## **6 GLOBAL NEXT-GENERATION IVD MARKET (BY PRODUCT), (\$BILLION), 2022-2033**

- 6.1 Overview
- 6.2 Consumables
- 6.3 Instruments
- 6.4 Software

## **7 GLOBAL NEXT-GENERATION IVD MARKET (BY TYPE), (\$BILLION), 2022-2033**

- 7.1 Overview
- 7.2 Core Laboratory Diagnostics
  - 7.2.1 Test Volume
  - 7.2.2 Market Size and Forecast
    - 7.2.2.1 Immunoassay
    - 7.2.2.2 Hematology
    - 7.2.2.3 Clinical Chemistry
    - 7.2.2.4 Other Core Laboratory Diagnostics
- 7.3 POC Testing
  - 7.3.1 Test Volume
  - 7.3.2 Market Size and Forecast
- 7.4 Molecular Diagnostics
  - 7.4.1 Test Volume
  - 7.4.2 Market Size and Forecast
    - 7.4.2.1 PCR
    - 7.4.2.2 NGS
    - 7.4.2.3 INAAT
    - 7.4.2.4 Microarray
    - 7.4.2.5 ISH
    - 7.4.2.6 Immunohistochemistry
    - 7.4.2.7 Other Molecular Diagnostics

## **8 GLOBAL NEXT-GENERATION IVD MARKETS (BY APPLICATION), \$BILLION, 2022-2033**

- 8.1 Overview
- 8.2 Diabetes
  - 8.2.1 Type
  - 8.2.2 Type
- 8.3 Infectious Diseases
  - 8.3.1 Tuberculosis

- 8.3.2 Malaria
- 8.3.3 Hepatitis
- 8.3.4 Other Infectious Diseases
- 8.4 Oncology/Cancer
  - 8.4.1 Solid Tumor
  - 8.4.2 Hematological Malignancies
- 8.5 Cardiology
  - 8.5.1 Cardiac Ischemia
  - 8.5.2 Coronary Artery Diseases
- 8.6 Other Applications

## **9 GLOBAL NEXT-GENERATION IVD MARKET (BY END USER), (\$BILLION), 2022-2033**

- 9.1 Overview
  - 9.1.1 Hospitals and Clinics
  - 9.1.2 Diagnostic Laboratories
  - 9.1.3 Academic and Research Institutions
  - 9.1.4 Other End Users

## **10 GLOBAL NEXT-GENERATION IVD MARKET, BY REGION, \$MILLION, 2022-2033**

- 10.1 Overview
- 10.2 North America
  - 10.2.1 Market Dynamics
  - 10.2.2 Market Size and Forecast
    - 10.2.2.1 North America Next-Generation IVD Market (by End User)
    - 10.2.2.2 North America Next-Generation IVD Market (by Type)
      - 10.2.2.2.1 North America Next-Generation Core Laboratory IVD Market, (by Type)
    - 10.2.2.3 North America Next-Generation IVD Market (by Country)
      - 10.2.2.3.1 U.S.
        - 10.2.2.3.1.1 Market Size and Forecast
          - 10.2.2.3.1.1.1 U.S. Next-Generation IVD Market (by End User)
          - 10.2.2.3.1.1.2 U.S. Next-Generation IVD Market (by Type)
      - 10.2.2.3.2 Canada
        - 10.2.2.3.2.1 Market Size and Forecast
          - 10.2.2.3.2.1.1 Canada Next-Generation IVD Market (by End User)
          - 10.2.2.3.2.1.2 Canada Next-Generation IVD Market (by Type)
- 10.3 Europe

### 10.3.1 Market Dynamics

### 10.3.2 Market Size and Forecast

#### 10.3.2.1 Europe Next-Generation IVD Market (by End User)

#### 10.3.2.2 Europe Next-Generation IVD Market (by Type)

##### 10.3.2.2.1 Europe Next-Generation Core Laboratory IVD Market, (by Type)

#### 10.3.2.3 Europe Next-Generation IVD Market (by Country)

##### 10.3.2.3.1 Germany

###### 10.3.2.3.1.1 Market Size and Forecast

###### 10.3.2.3.1.1.1 Germany Next-Generation IVD Market (by End User)

###### 10.3.2.3.1.1.2 Germany Next-Generation IVD Market (by Type)

##### 10.3.2.3.2 France

###### 10.3.2.3.2.1 Market Size and Forecast

###### 10.3.2.3.2.1.1 France Next-Generation IVD Market (by End User)

###### 10.3.2.3.2.1.2 France Next-Generation IVD Market (by Type)

##### 10.3.2.3.3 U.K.

###### 10.3.2.3.3.1 Market Size and Forecast

###### 10.3.2.3.3.1.1 U.K. Next-Generation IVD Market (by End User)

###### 10.3.2.3.3.1.2 U.K. Next-Generation IVD Market (by Type)

##### 10.3.2.3.4 Italy

###### 10.3.2.3.4.1 Market Size and Forecast

###### 10.3.2.3.4.1.1 Italy Next-Generation IVD Market (by End User)

###### 10.3.2.3.4.1.2 Italy Next-Generation IVD Market (by Type)

##### 10.3.2.3.5 Spain

###### 10.3.2.3.5.1 Market Size and Forecast

###### 10.3.2.3.5.1.1 Spain Next-Generation IVD Market (by End User)

###### 10.3.2.3.5.1.2 Spain Next-Generation IVD Market (by Type)

##### 10.3.2.3.6 Rest-of-Europe

###### 10.3.2.3.6.1 Market Size and Forecast

###### 10.3.2.3.6.1.1 Rest-of-Europe Next-Generation IVD Market (by End User)

###### 10.3.2.3.6.1.2 Rest-of-Europe Next-Generation IVD Market (by Type)

### 10.4 Asia-Pacific

#### 10.4.1 Market Dynamics

#### 10.4.2 Market Size and Forecast

##### 10.4.2.1 Asia-Pacific Next-Generation IVD Market (by End User)

##### 10.4.2.2 Asia-Pacific Next-Generation IVD Market (by Type)

###### 10.4.2.2.1 Asia-Pacific Next-Generation Core Laboratory IVD Market, (by Type)

##### 10.4.2.3 Asia-Pacific Next-Generation IVD Market (by Country)

###### 10.4.2.3.1 China

###### 10.4.2.3.1.1 Market Size and Forecast

- 10.4.2.3.1.1.1 China Next-Generation IVD Market (by End User)
- 10.4.2.3.1.1.2 China Next-Generation IVD Market (by Type)
- 10.4.2.3.2 Japan
  - 10.4.2.3.2.1 Market Size and Forecast
    - 10.4.2.3.2.1.1 Japan Next-Generation IVD Market (by End User)
    - 10.4.2.3.2.1.2 Japan Next-Generation IVD Market (by Type)
- 10.4.2.3.3 India
  - 10.4.2.3.3.1 Market Size and Forecast
    - 10.4.2.3.3.1.1 India Next-Generation IVD Market (by End User)
    - 10.4.2.3.3.1.2 India Next-Generation IVD Market (by Type)
- 10.4.2.3.4 Australia
  - 10.4.2.3.4.1 Market Size and Forecast
    - 10.4.2.3.4.1.1 Australia Next-Generation IVD Market (by End User)
    - 10.4.2.3.4.1.2 Australia Next-Generation IVD Market (by Type)
- 10.4.2.3.5 South Korea
  - 10.4.2.3.5.1 Market Size and Forecast
    - 10.4.2.3.5.1.1 South Korea Next-Generation IVD Market (by End User)
    - 10.4.2.3.5.1.2 South Korea Next-Generation IVD Market (by Type)
- 10.4.2.3.6 Rest-of-Asia-Pacific
  - 10.4.2.3.6.1 Market Size and Forecast
    - 10.4.2.3.6.1.1 Rest-of-Asia-Pacific Next-Generation IVD Market (by End User)
    - 10.4.2.3.6.1.2 Rest-of-Asia-Pacific Next-Generation IVD Market (by Type)
- 10.5 Latin America
  - 10.5.1 Market Dynamics
  - 10.5.2 Market Size and Forecast
    - 10.5.2.1 Latin America Next-Generation IVD Market (by End User)
    - 10.5.2.2 Latin America Next-Generation IVD Market (by Type)
      - 10.5.2.2.1 Latin America Next-Generation Core Laboratory IVD Market, (by Type)
    - 10.5.2.3 Latin America Next-Generation IVD Market (by Country)
      - 10.5.2.3.1 Brazil
        - 10.5.2.3.1.1 Market Size and Forecast
          - 10.5.2.3.1.1.1 Brazil Next-Generation IVD Market (by End User)
          - 10.5.2.3.1.1.2 Brazil Next-Generation IVD Market (by Type)
      - 10.5.2.3.2 Mexico
        - 10.5.2.3.2.1 Market Size and Forecast
          - 10.5.2.3.2.1.1 Mexico Next-Generation IVD Market (by End User)
          - 10.5.2.3.2.1.2 Mexico Next-Generation IVD Market (by Type)
      - 10.5.2.3.3 Rest-of-Latin America
        - 10.5.2.3.3.1 Market Size and Forecast

- 10.5.2.3.3.1.1 Rest-of-Latin America Next-Generation IVD Market (by End User)
- 10.5.2.3.3.1.2 Rest-of-Latin America Next-Generation IVD Market (by Type)
- 10.6 Middle East and Africa
  - 10.6.1 Market Dynamics
  - 10.6.2 Market Size and Forecast
    - 10.6.2.1 Middle East and Africa Next-Generation IVD Market (by End User)
    - 10.6.2.2 Middle East and Africa Next-Generation IVD Market (by Type)
      - 10.6.2.2.1 Middle East and Africa Next-Generation Core Laboratory IVD Market, (by Type)

## **11 COMPANY PROFILES**

- 11.1 Overview
- 11.2 Global Next-Generation IVD Market Ecosystem Active Players
- 11.3 Abbott Laboratories
  - 11.3.1 Company Overview
  - 11.3.2 Role of Abbott Laboratories in the Global Next-Generation IVD Market
  - 11.3.3 Financials
  - 11.3.4 Recent Developments
    - 11.3.4.1 Business Strategies
  - 11.3.5 Analyst Perspective
- 11.4 Agilent Technologies, Inc.
  - 11.4.1 Company Overview
  - 11.4.2 Role of Agilent Technologies, Inc. in the Global Next-Generation IVD Market
  - 11.4.3 Financials
  - 11.4.4 Recent Developments
    - 11.4.4.1 Corporate Strategies
    - 11.4.4.2 Business Strategies
  - 11.4.5 Analyst Perspective
- 11.5 Becton, Dickinson and Company
  - 11.5.1 Company Overview
  - 11.5.2 Role of Becton, Dickinson and Company in the Global Next-Generation IVD Market
  - 11.5.3 Financials
  - 11.5.4 Recent Developments
    - 11.5.4.1 Corporate Strategies
    - 11.5.4.2 Business Strategies
  - 11.5.5 Analyst Perspective
- 11.6 bioMérieux SA (BioFire Diagnostics)



- 11.6.1 Company Overview
- 11.6.2 Role of bioMérieux SA (BioFire Diagnostics) in the Global Next-Generation IVD Market
- 11.6.3 Financials
- 11.6.4 Recent Developments
  - 11.6.4.1 Corporate Strategies
  - 11.6.4.2 Business Strategies
- 11.6.5 Analyst Perspective
- 11.7 Bio-Rad Laboratories, Inc.
  - 11.7.1 Company Overview
  - 11.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Next-Generation IVD Market
  - 11.7.3 Financials
  - 11.7.4 Recent Developments
    - 11.7.4.1 Business Strategies
  - 11.7.5 Analyst Perspective
- 11.8 Danaher Corporation
  - 11.8.1 Company Overview
  - 11.8.2 Role of Danaher Corporation in the Global Next-Generation IVD Market
  - 11.8.3 Financials
  - 11.8.4 Recent Developments
    - 11.8.4.1 Corporate Strategies
    - 11.8.4.2 Business Strategies
  - 11.8.5 Analyst Perspective
- 11.9 F. Hoffmann-La Roche Ltd. (Roche Molecular Systems, Inc.)
  - 11.9.1 Company Overview
  - 11.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Next-Generation IVD Market
  - 11.9.3 Financials
  - 11.9.4 Recent Developments
    - 11.9.4.1 Business Strategies
  - 11.9.5 Analyst Perspective
- 11.1 Guardant Health
  - 11.10.1 Company Overview
  - 11.10.2 Role of Guardant Health in the Global Next-Generation IVD Market
  - 11.10.3 Financials
  - 11.10.4 Analyst Perspective
- 11.11 Illumina, Inc.
  - 11.11.1 Company Overview
  - 11.11.2 Role of Illumina, Inc. in the Global Next-Generation IVD Market
  - 11.11.3 Financials



- 11.11.4 Recent Developments
  - 11.11.4.1 Corporate Strategies
  - 11.11.4.2 Business Strategies
- 11.11.5 Analyst Perspective
- 11.12 Invivoscribe, Inc.
  - 11.12.1 Company Overview
  - 11.12.2 Role of Invivoscribe, Inc. in the Global Next-Generation IVD Market
  - 11.12.3 Recent Developments
    - 11.12.3.1 Corporate Strategies
  - 11.12.4 Analyst Perspective
- 11.13 PerkinElmer Inc.
  - 11.13.1 Company Overview
  - 11.13.2 Role of PerkinElmer Inc. in the Global Next-Generation IVD Market
  - 11.13.3 Financials
  - 11.13.4 Recent Developments
    - 11.13.4.1 Corporate Strategies
    - 11.13.4.2 Business Strategies
  - 11.13.5 Analyst Perspective
- 11.14 QIAGEN N.V.
  - 11.14.1 Company Overview
  - 11.14.2 Role of QIAGEN N.V. in the Global Next-Generation IVD Market
  - 11.14.3 Financials
  - 11.14.4 Recent Developments
    - 11.14.4.1 Corporate Strategies
    - 11.14.4.2 Business Strategies
  - 11.14.5 Analyst Perspective
- 11.15 Quest Diagnostics Incorporated
  - 11.15.1 Company Overview
  - 11.15.2 Role of Quest Diagnostics Incorporated in the Global Next-Generation IVD Market
  - 11.15.3 Financials
  - 11.15.4 Analyst Perspective
- 11.16 Sysmex Corporation
  - 11.16.1 Company Overview
  - 11.16.2 Role of Sysmex Corporation in the Global Next-Generation IVD Market
  - 11.16.3 Financials
  - 11.16.4 Recent Developments
    - 11.16.4.1 Business Strategies
  - 11.16.5 Analyst Perspective

## 11.17 Laboratory Corporation of America Holdings.

### 11.17.1 Company Overview

### 11.17.2 Role of Laboratory Corporation of America Holdings. in Global Next-Generation IVD Market

### 11.17.3 Financials

### 11.17.4 Recent Developments

#### 11.17.4.1 Business Strategies

### 11.17.5 Analyst's Perspective

## 11.18 Myriad Genetics, Inc.

### 11.18.1 Company Overview

### 11.18.2 Role of Myriad Genetics, Inc. in the Global Next-Generation IVD Market

### 11.18.3 Financials

### 11.18.4 Analyst Perspective

## 11.19 Siemens Healthineers AG

### 11.19.1 Company Overview

### 11.19.2 Role of Siemens Healthineers AG in the Global Next-Generation IVD Market

### 11.19.3 Financials

### 11.19.4 Recent Developments

#### 11.19.4.1 Corporate Strategies

#### 11.19.4.2 Business Strategies

### 11.19.5 Analyst Perspective

## 11.2 Tempus

### 11.20.1 Company Overview

### 11.20.2 Role of Tempus in the Global Next-Generation IVD Market

### 11.20.3 Recent Developments

#### 11.20.3.1 Business Strategies

### 11.20.4 Analyst Perspective

## 11.21 Thermo Fisher Scientific Inc.

### 11.21.1 Company Overview

### 11.21.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation IVD Market

### 11.21.3 Financials

### 11.21.4 Recent Developments

#### 11.21.4.1 Corporate Strategies

#### 11.21.4.2 Business Strategies

### 11.21.5 Analyst Perspective

## 11.22 Emerging Companies

### 11.22.1 Geneseeq Technology Inc.

### 11.22.2 Genes2Me

11.22.3 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

11.22.4 Spindiag GmbH

## List Of Figures

### LIST OF FIGURES

Figure 1: Facts about Global Next-Generation IVD Market

Figure 2: Equipment's used for Next-Generation In-Vitro Diagnostics

Figure 3: Global Next-Generation IVD Market, \$Billion, 2022 and 2033

Figure 4: Trend Analysis of Next-Generation In-vitro Diagnostics Ecosystem

Figure 5: Common Chronic Conditions for Population Above 65 years

Figure 6: Key Challenges in the Global Next-Generation IVD Market based on Primary Respondents

Figure 7: New In-Vitro Diagnostics Regulations (IVDR) and Medical Device Regulation (MDR)

Figure 8: Major Highlights Witnessed in the Next-Generation IVD Market During COVID-19 Impact

Figure 9: Role of POC Diagnostics in Next-Generation IVD Market During Pandemic

Figure 10: Leading and Emerging Companies in the Next-Generation IVD Ecosystem

Figure 11: Leading Companies in the Next-Generation IVD Ecosystem and Their Market Share (%)

Figure 12: Key Developments Undertaken by Companies in the Next-Generation IVD Market, July 2019-June 2023

Figure 13: Product Benchmarking of Next-Generation In-Vitro Diagnostics Ecosystem (by Test)

Figure 14: Global Next-Generation IVD Market (by Type), Share (%), 2022 and 2033

Figure 15: Global Next-Generation IVD Market (by Product), Share (%), 2022 and 2033

Figure 16: Global Next-Generation IVD Market (by Application), Share (%), 2022 and 2033

Figure 17: Global Next-Generation IVD Market (by End User), Share (%), 2022 and 2033

Figure 18: Global Next-Generation In-Vitro Diagnostics Market (by Region), \$Billion, 2022 and 2033

Figure 19: Europe Next-Generation IVD Market, Market Snapshot

Figure 20: Global Next-Generation IVD Market Segmentation

Figure 21: Global Next-Generation IVD Market: Research Methodology

Figure 22: Primary Research Methodology

Figure 23: Bottom-Up Approach (Segment-Wise Analysis)

Figure 24: Top-Down Approach (Segment-Wise Analysis)

Figure 25: Global Next-Generation IVD Market, \$Billion, 2022-2033

Figure 26: Product Benchmarking of Next-Generation In-vitro Diagnostics Market (by

Type)

Figure 27: In-Vitro Diagnostic Trends during the COVID-19 Pandemic

Figure 28: Timeline of IVDR 2017/746

Figure 29: Global Next-Generation IVD Market Dynamics

Figure 30: Factors Contributing to Growing Demand of POC Testing

Figure 31: Current Trend in In-Vitro Diagnostics: From Centralized Laboratory to Point-of-Care Testing

Figure 32: Annual Global Mortality by Chronic Illness in 1990, 2002, and 2020

Figure 33: Trend in COVID-19 Diagnostic Test Development and the Used Technology

Figure 34: Top Challenges in the IVDR Compliance

Figure 35: Key Area of Focus by Next-Generation IVD Companies

Figure 36: Share of Key Developments, July 2019-June 2023

Figure 37: Share of Acquisitions (by Company), July 2019-June 2023

Figure 38: Share of Synergistic Activities (by Company), July 2019-June 2023

Figure 39: Share of Product Launches and Approvals (by Company), July 2019-June 2023

Figure 40: Share of Business Expansions, Fundings, and Other Activities (by Company), July 2019-June 2023

Figure 41: Market Share Analysis of Global Next-Generation IVD Market (by Company), 2022

Figure 42: Growth Share Analysis for Global Next-Generation IVD Market (by Product), 2022

Figure 43: Global Next-Generation IVD Market (by Product)

Figure 44: Global Next-Generation IVD Market (by Product), \$Billion, 2022 and 2033

Figure 45: Global Next-Generation IVD Market (Consumables), \$Billion, 2022-2033

Figure 46: Global Next-Generation IVD Market (Instruments), \$Billion, 2022-2033

Figure 47: Global Next-Generation IVD Market (Software), \$Billion, 2022-2033

Figure 48: Global Next-Generation IVD Market (by Type)

Figure 49: Global Next-Generation IVD Market (by Type), \$Billion, 2022 and 2033

Figure 50: Global Next-Generation IVD Market (Core Laboratory Diagnostics), Thousand Units, 2022-2033

Figure 51: Global Next-Generation IVD Market (Core Laboratory Diagnostics), \$Billion, 2022-2033

Figure 52: Global Next-Generation IVD Market (Immunoassay), \$Billion, 2022-2033

Figure 53: Global Next-Generation IVD Market (Hematology), \$Billion, 2022-2033

Figure 54: Global Next-Generation IVD Market (Clinical Chemistry), \$Billion, 2022-2033

Figure 55: Global Next-Generation IVD Market (Other Core Laboratory Diagnostics), \$Billion, 2022-2033

Figure 56: Global Next-Generation IVD Market (POC Testing), Thousand Units,

2022-2033

Figure 57: Global Next-Generation IVD Market (POC Testing), \$Billion, 2022-2033

Figure 58: Global Next-Generation IVD Market (Molecular Diagnostics), Thousand Units, 2022-2033

Figure 59: Global Next-Generation IVD Market (Molecular Diagnostics), \$Billion, 2022-2033

Figure 60: Global Next-Generation IVD Market (PCR), \$Billion, 2022-2033

Figure 61: Global Next-Generation IVD Market (NGS), \$Billion, 2022-2033

Figure 62: Global Next-Generation IVD Market (INAAT), \$Billion, 2022-2033

Figure 63: Global Next-Generation IVD Market (Microarray), \$Billion, 2022-2033

Figure 64: Global Next-Generation IVD Market (ISH), \$Billion, 2022-2033

Figure 65: Global Next-Generation IVD Market (Immunohistochemistry), \$Billion, 2022-2033

Figure 66: Global Next-Generation IVD Market (Other Molecular Diagnostics), \$Billion, 2022-2033

Figure 67: Global Next-Generation IVD Market (by Application)

Figure 68: Global Next-Generation IVD Market (by Application), Share (%), 2022 and 2033

Figure 69: Global Next-Generation IVD Market (Diabetes), \$Billion, 2022-2033

Figure 70: Global Next-Generation IVD Market (Type 1), \$Billion, 2022-2033

Figure 71: Global Next-Generation IVD Market (Type 2), \$Billion, 2022-2033

Figure 72: Global Next-Generation IVD Market (Infectious Diseases), \$Billion, 2022-2033

Figure 73: Global Next-Generation IVD Market (Tuberculosis), \$Billion, 2022-2033

Figure 74: Global Next-Generation IVD Market (Malaria), \$Billion, 2022-2033

Figure 75: Global Next-Generation IVD Market (Hepatitis), \$Billion, 2022-2033

Figure 76: Global Next-Generation IVD Market (Other Infectious Diseases), \$Billion, 2022-2033

Figure 77: Global Next-Generation IVD Market (Oncology/Cancer), \$Billion, 2022-2033

Figure 78: Global Next-Generation IVD Market (Solid Tumor), \$Billion, 2022-2033

Figure 79: Global Next-Generation IVD Market (Hematological Malignancies), \$Billion, 2022-2033

Figure 80: Global Next-Generation IVD Market (Cardiology), \$Billion, 2022-2033

Figure 81: Global Next-Generation IVD Market (Cardiac Ischemia), \$Billion, 2022-2033

Figure 82: Global Next-Generation IVD Market (Coronary Artery Diseases), \$Billion, 2022-2033

Figure 83: Global Next-Generation IVD Market (Other Applications), \$Billion, 2022-2033

Figure 84: Global Next-Generation IVD Market (by End User)

Figure 85: Global Next-Generation IVD Market (by End User), Share (%), 2022 and



2033

Figure 86: Global Next-Generation IVD Market (Hospitals and Clinics), \$Billion, 2022-2033

Figure 87: Global Next-Generation IVD Market (Diagnostic Laboratories), \$Billion, 2022-2033

Figure 88: Global Next-Generation IVD Market (Academic and Research Institutes), \$Billion, 2022-2033

Figure 89: Global Next-Generation IVD Market (Other End Users), \$Billion, 2022-2033

Figure 90: Global Next-Generation IVD Market (by Region), Share (%), 2022

Figure 91: Global Next-Generation IVD Market (by Region), \$Billion, 2022-2033

Figure 92: North America Next-Generation IVD Market, \$Billion, 2022-2033

Figure 93: North America Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 94: North America Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 95: North America Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 96: North America Next-Generation IVD Market (by Country), \$Billion, 2022-2033

Figure 97: Factors Accelerating U.S. Next-Generation IVD Market

Figure 98: U.S. Next-Generation IVD Market, \$Billion, 2022-2033

Figure 99: U.S. Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 100: U.S. Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 101: U.S. Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 102: Canada Next-Generation IVD Market, \$Billion, 2022-2033

Figure 103: Canada Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 104: Canada Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 105: Canada Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 106: Europe Next-Generation IVD Market, \$Billion, 2022-2033

Figure 107: Europe Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 108: Europe Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 109: Europe Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 110: Europe Next-Generation IVD Market (by Country), \$Billion, 2022-2033

Figure 111: Germany Next-Generation IVD Market, \$Billion, 2022-2033

Figure 112: Germany Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 113: Germany Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 114: Germany Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 115: France Next-Generation IVD Market, \$Billion, 2022-2033

Figure 116: France Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 117: France Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 118: France Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 119: U.K. Next-Generation IVD Market, \$Billion, 2022-2033

Figure 120: U.K. Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 121: U.K. Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 122: U.K. Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 123: Italy Next-Generation IVD Market, \$Billion, 2022-2033

Figure 124: Italy Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 125: Italy Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 126: Italy Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 127: Spain Next-Generation IVD Market, \$Billion, 2022-2033

Figure 128: Spain Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 129: Spain Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 130: Spain Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 131: Rest-of-Europe Next-Generation IVD Market, \$Billion, 2022-2033

Figure 132: Rest-of-Europe Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 133: Rest-of-Europe Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 134: Rest-of-Europe Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 135: Asia-Pacific Next-Generation IVD Market, \$Billion, 2022-2033

Figure 136: Asia-Pacific Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 137: Asia-Pacific Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 138: Asia-Pacific Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 139: Asia-Pacific Next-Generation IVD Market (by Country), \$Billion, 2022-2033

Figure 140: China Next-Generation IVD Market, \$Billion, 2022-2033

Figure 141: China Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 142: China Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 143: China Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 144: Japan Next-Generation IVD Market, \$Billion, 2022-2033



Figure 145: Japan Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 146: Japan Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 147: Japan Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 148: India Next-Generation IVD Market, \$Billion, 2022-2033

Figure 149: India Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 150: India Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 151: India Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 152: Australia Next-Generation IVD Market, \$Billion, 2022-2033

Figure 153: Australia Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 154: Australia Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 155: Australia Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 156: South Korea Next-Generation IVD Market, \$Billion, 2022-2033

Figure 157: South Korea Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 158: South Korea Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 159: South Korea Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 160: Rest-of-Asia-Pacific Next-Generation IVD Market, \$Billion, 2022-2033

Figure 161: Rest-of-Asia-Pacific Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 162: Rest-of-Asia-Pacific Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 163: Rest-of-Asia-Pacific Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 164: Latin America Next-Generation IVD Market, \$Billion, 2022-2033

Figure 165: Latin America Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 166: Latin America Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 167: Latin America Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 168: Latin America Next-Generation IVD Market (by Country), \$Billion, 2022-2033

Figure 169: Brazil Next-Generation IVD Market, \$Billion, 2022-2033

Figure 170: Brazil Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 171: Brazil Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 172: Brazil Next-Generation Core Laboratory IVD Market (by Type), \$Billion,

2022-2033

Figure 173: Mexico Next-Generation IVD Market, \$Billion, 2022-2033

Figure 174: Mexico Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 175: Mexico Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 176: Mexico Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 177: Rest-of-Latin America Next-Generation IVD Market, \$Billion, 2022-2033

Figure 178: Rest-of-Latin America Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 179: Rest-of-Latin America Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 180: Rest-of-Latin America Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 181: Middle East and Africa Next-Generation IVD Market, \$Billion, 2022-2033

Figure 182: Middle East and Africa Next-Generation IVD Market (by End User), \$Billion, 2022-2033

Figure 183: Middle East and Africa Next-Generation IVD Market (by Type), \$Billion, 2022-2033

Figure 184: Middle East and Africa Next-Generation Core Laboratory IVD Market (by Type), \$Billion, 2022-2033

Figure 185: Total Number of Companies Profiled

Figure 186: Abbott Laboratories: Product Portfolio

Figure 187: Abbott Laboratories: Overall Financials, \$Million, 2020-2022

Figure 188: Abbott Laboratories: Revenue (by Segment), \$Million, 2020-2022

Figure 189: Abbott Laboratories: Revenue (by Region), \$Million, 2020-2022

Figure 190: Abbott Laboratories: R&D Expenditure, \$Million, 2020-2022

Figure 191: Agilent Technologies, Inc.: Product Portfolio

Figure 192: Agilent Technologies, Inc.: Overall Financials, \$Million, 2020-2022

Figure 193: Agilent Technologies, Inc.: Net Revenue (by Segment), \$Million, 2020-2022

Figure 194: Agilent Technologies, Inc.: Net Revenue (by Region), \$Million, 2020-2022

Figure 195: Agilent Technologies, Inc.: R&D Expenditure, \$Million, 2020-2022

Figure 196: Becton, Dickinson and Company: Product Portfolio

Figure 197: Becton, Dickinson and Company: Overall Financials, \$Million, 2020-2022

Figure 198: Becton, Dickinson and Company: Revenue (by Segment), \$Million, 2020-2022

Figure 199: Becton, Dickinson and Company: Revenue (by Region), \$Million, 2020-2022

Figure 200: Becton, Dickinson and Company: R&D Expenditure, \$Million, 2020-2022

Figure 201: bioMérieux SA (BioFire Diagnostics): Product Portfolio

- Figure 202: bioMérieux SA (BioFire Diagnostics): Overall Financials, \$Million, 2020-2022
- Figure 203: bioMérieux SA (BioFire Diagnostics): Revenue (by Segment), \$Million, 2020-2022
- Figure 204: bioMérieux SA (BioFire Diagnostics): Revenue (by Region), \$Million, 2020-2022
- Figure 205: bioMérieux SA (BioFire Diagnostics): R&D Expenditure, \$Million, 2020-2022
- Figure 206: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 207: Bio-Rad Laboratories, Inc.: Overall Financials, \$Million, 2020-2022
- Figure 208: Bio-Rad Laboratories, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 209: Bio-Rad Laboratories, Inc.: Revenue (by Region), \$Million, 2020-2022
- Figure 210: Bio-Rad Laboratories, Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 211: Danaher Corporation: Product Portfolio
- Figure 212: Danaher Corporation: Overall Financials, \$Million, 2020-2022
- Figure 213: Danaher Corporation: Revenue (by Segment), \$Million, 2020-2022
- Figure 214: Danaher Corporation: Revenue (by Region), \$Million, 2020-2022
- Figure 215: Danaher Corporation: R&D Expenditure, \$Million, 2020-2022
- Figure 216: F. Hoffmann-La Roche Ltd.: Product Portfolio
- Figure 217: F. Hoffmann-La Roche Ltd.: Overall Financials, \$Million, 2020-2022
- Figure 218: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), \$Million, 2020-2022
- Figure 219: F. Hoffmann-La Roche Ltd.: Revenue (by Region), \$Million, 2020-2022
- Figure 220: F. Hoffmann-La Roche Ltd.: R&D Expenditure, \$Million, 2020-2022
- Figure 221: Guardant Health: Product Portfolio
- Figure 222: Guardant Health: Overall Financials, \$Million, 2020-2022
- Figure 223: Guardant Health: Revenue (by Segment), \$Million, 2020-2022
- Figure 224: Guardant Health: Revenue (by Region), \$Million, 2020-2022
- Figure 225: Guardant Health: R&D Expenditure, \$Million, 2020-2022
- Figure 226: Illumina, Inc.: Product Portfolio
- Figure 227: Illumina, Inc.: Overall Financials, \$Million, 2020-2022
- Figure 228: Illumina, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 229: Illumina, Inc.: Revenue (by Region), \$Million, 2020-2022
- Figure 230: Illumina, Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 231: Invivoscribe, Inc.: Product Portfolio
- Figure 232: PerkinElmer Inc.: Product Portfolio
- Figure 233: PerkinElmer Inc.: Overall Financials, \$Million, 2020-2022
- Figure 234: PerkinElmer Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 235: PerkinElmer Inc.: Revenue (by Region), \$Million, 2020-2022
- Figure 236: PerkinElmer Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 237: QIAGEN N.V.: Product Portfolio

- Figure 238: QIAGEN N.V.: Overall Financials, \$Million, 2020-2022
- Figure 239: QIAGEN N.V.: Revenue (by Segment), \$Million, 2020-2022
- Figure 240: QIAGEN N.V.: Revenue (by Region), \$Million, 2020-2022
- Figure 241: QIAGEN N.V.: R&D Expenditure, \$Million, 2020-2022
- Figure 242: Quest Diagnostics Incorporated: Product Portfolio
- Figure 243: Quest Diagnostics Incorporated: Overall Financials, \$Million, 2020-2022
- Figure 244: Quest Diagnostics Incorporated: Revenue (by Segment), \$Million, 2020-2022
- Figure 245: Sysmex Corporation: Product Portfolio
- Figure 246: Sysmex Corporation: Overall Financials, \$Million, 2020-2022
- Figure 247: Sysmex Corporation: Revenue (by Segment), \$Million, 2020-2022
- Figure 248: Sysmex Corporation: Revenue (by Region), \$Million, 2020-2022
- Figure 249: Sysmex Corporation: R&D Expenditure, \$Million, 2020-2022
- Figure 250: Laboratory Corporation of America Holdings.: Product Portfolio
- Figure 251: Laboratory Corporation of America Holdings.: Overall Financials, \$Million, 2020-2022
- Figure 252: Laboratory Corporation of America Holdings.: Revenue (by Segment), \$Million, 2020-2022
- Figure 253: Laboratory Corporation of America Holdings.: Revenue (by Region), \$Million, 2020-2022
- Figure 254: Myriad Genetics, Inc.: Product Portfolio
- Figure 255: Myriad Genetics, Inc.: Overall Financials, (\$Million), 2020-2022
- Figure 256: Myriad Genetics, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 257: Myriad Genetics, Inc.: R&D Expenditure, (\$Million), 2020-2022
- Figure 258: Siemens Healthineers AG: Product Portfolio
- Figure 259: Siemens Healthineers AG: Overall Financials, \$Million, 2020-2022
- Figure 260: Siemens Healthineers AG: Revenue (by Region), \$Million, 2020-2022
- Figure 261: Siemens Healthineers AG: R&D Expenditure, \$Million, 2020-2022
- Figure 262: Tempus: Product Portfolio
- Figure 263: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 264: Thermo Fisher Scientific Inc.: Overall Financials, \$Million, 2020-2022
- Figure 265: Thermo Fisher Scientific Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 266: Thermo Fisher Scientific Inc.: Revenue (by Region), \$Million, 2020-2022
- Figure 267: Thermo Fisher Scientific Inc.: R&D Expenditure, \$Million, 2020-2022

## List Of Tables

### LIST OF TABLES

Table 1: Impact Analysis of Market Drivers, and Restraints on the Global Next-Generation IVD Market

Table 2: Impact of COVID-19 on Different Countries

Table 3: Likert Scale

Table 4: Impact Analysis of Market Drivers

Table 5: Impact Analysis of Market Restraints

Table 6: Impact Analysis of Market Opportunities

Table 7: Technology Offered by Next-Generation IVD Ecosystem

Table 8: Examples of Expansion Strategy by Global Next-Generation IVD Market Players

Table 9: Companies Offering Next-Generation-IVD Kits

Table 10: Companies Offering Next-Generation IVD Instruments

Table 11: Companies Offering Next-Generation IVD Software

Table 12: Companies Offering POC Test

Table 13: North America: Market Dynamics

Table 14: Europe: Market Dynamics

Table 15: Asia-Pacific: Market Dynamics

Table 16: Latin America: Market Dynamics

Table 17: Middle East and Africa: Market Dynamics

Table 18: Global Next-Generation IVD Market, Active Players

## I would like to order

Product name: Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company, Throughput, Technology Type, Sequencing, Application, End User, and Country Analysis - Analysis and Forecast, 2023-2033

Product link: <https://marketpublishers.com/r/N8EFC1210311EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N8EFC1210311EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970